Therefore, evaluation of PD-L1 expression by immunohistochemistry on tumor specimens is playing a critical role in the selection of patients who could benefit from therapy with PD1/PDL1-specific checkpoint inhibitors. The gene discussed is PDCD1; the disease is neoplasm.